首次诊断冠心病患者斑块体积的预后价值:PROMISE随机临床试验子研究
该研究为PROMISE随机试验的事后分析,纳入4267例无已知冠心病的有症状门诊患者,接受CCTA并基于核心实验室定量斑块测量。结果显示总斑块负荷和非钙化斑块负荷独立预测MACE,总斑块体积≥87 mm³、总斑块负荷≥35%和非钙化斑块负荷≥20%均与MACE风险近2倍增加相关。
要点
- 总斑块负荷和非钙化斑块负荷独立预测MACE,校正临床风险因素、他汀使用和定性CCTA发现后仍显著。
- 总斑块体积≥87 mm³、总斑块负荷≥35%和非钙化斑块负荷≥20%均与MACE风险近2倍增加相关。
- 定量CCTA斑块分析在早期冠心病中的临床效用尚需前瞻性评估。
核心结论
- 在无已知冠心病的有症状患者中,冠状动脉斑块体积和负荷较低,但与冠心病风险因素相关,并独立预测MACE。
- 基于定量CCTA的心血管风险估计在早期冠心病中的临床效用需要前瞻性评估。
研究设计与样本
- 该研究为PROMISE随机临床试验的事后分析,纳入北美193个临床中心的前瞻性随机试验中接受CCTA的无已知冠心病有症状门诊患者。
- 试验于2010年7月27日至2014年10月31日进行,本报告数据分析于2021年1月至2024年7月。
- 共纳入4267例患者,平均(SD)年龄60.4(8.2)岁,女性2199例(51.5%),男性2068例(48.5%)。
主要发现
- 总斑块体积中位数(IQR)为39.8 mm³(0-167)mm³。
- 总斑块体积≥87 mm³、总斑块负荷≥35%和非钙化斑块负荷≥20%的最佳截点均与MACE风险近2倍增加相关(TPV:aHR 2.07,95%CI 1.24-3.49;TPB:aHR 1.96,95%CI 1.21-3.17;NCPB:aHR 1.77,95%CI 1.12-2.82)。
关键数值与推荐
- 总斑块体积≥87 mm³与MACE风险增加相关(aHR 2.07,95%CI 1.24-3.49)。
- 总斑块负荷≥35%与MACE风险增加相关(aHR 1.96,95%CI 1.21-3.17)。
- 非钙化斑块负荷≥20%与MACE风险增加相关(aHR 1.77,95%CI 1.12-2.82)。
临床怎么用
- 对于无已知冠心病的有症状门诊患者,定量CCTA斑块分析(总斑块体积、总斑块负荷、非钙化斑块负荷)可提供增量预后信息。
- 总斑块体积≥87 mm³、总斑块负荷≥35%和非钙化斑块负荷≥20%提示MACE风险近2倍增加,可能有助于风险分层。
- 定量CCTA斑块分析的临床效用尚需前瞻性评估,暂不能常规推荐用于临床决策。
局限性
- 该研究为事后分析,结果需前瞻性验证。
- 定量CCTA斑块分析在早期冠心病中的临床效用尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite the increasing use of coronary computed tomographic angiography (CCTA) in patients with known or suspected coronary artery disease (CAD), comparatively little is known about its predictive value for adverse events or clinical applicability of volumetric plaque analysis. OBJECTIVE: To assess the incremental prognostic value of quantitative CAD measures in symptomatic outpatients without known CAD. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis involved a prospective randomized clinical trial conducted across 193 clinical sites in North America. Participants were symptomatic outpatients without known CAD who were randomized to receive CCTA. The trial was conducted from July 27, 2010, to October 31, 2014, and the data analyzed for this report from January 2021 to July 2024. EXPOSURES: Core laboratory-based quantitative plaque measures, including total plaque volume (TPV), calcified (CPV) and noncalcified (NCPV) plaque volume, low-attenuation plaque volume (LAPV), total plaque burden (TPB), and noncalcified plaque burden (NCPB), normalized with vessel volume. MAIN OUTCOMES AND MEASURES: The primary outcome was major adverse cardiovascular events MACE (composite of death, nonfatal myocardial infarction, or hospitalization for unstable angina). Optimal predictive cut points for plaque measures were identified using Euclidean distance methods and tested in multivariable Cox regression models. RESULTS: Among 4267 patients, the mean (SD) age was 60.4 (8.2) years; 2199 patients (51.5%) were female and 2068 (48.5%) were male. The median (IQR) TPV was 39.8 mm3 (0-167) mm3. Patients with TPV at the median or higher were older (mean [SD] age, 62.1 [8.4] vs 58.7 [7.5] years for those with lower than median TPV), more likely to be male (1286/2133 [60.3%] vs 782/2134 [36.6%], respectively), and had higher median (IQR) atherosclerotic cardiovascular disease risk scores (14.4 [8.8-24.0] vs 7.9 [4.5-13.4], respectively). TPB showed similar demographic associations. Both TPB and NCPB independently predicted MACE after adjusting for clinical risk factors, statin use, and qualitative CCTA findings (TPB: adjusted HR [aHR], 1.18; 95% CI, 1.05-1.34; P = .006; NCPB: aHR, 1.20; 95% CI, 1.05-1.37; P = .007). Optimal cutoffs of TPV 87 mm3 or greater, TPB 35% or greater, and NCPB 20% or greater were each associated with nearly a 2-fold increase in MACE risk (TPV: aHR, 2.07; 95% CI, 1.24-3.49; TPB: aHR, 1.96; 95% CI, 1.21-3.17; and NCPB: aHR, 1.77; 95% CI, 1.12-2.82). CONCLUSIONS AND RELEVANCE: In symptomatic patients without known CAD, coronary plaque volumes and burdens are low but are related to CAD risk factors and independently predictive of MACE. The clinical utility of quantitative CCTA-based cardiovascular risk estimation in early CAD requires prospective evaluation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01174550.
引用
- Karády J, Mayrhofer T, Brendel JM, et al. Prognostic Value of Plaque Volume in Patients With First Diagnosis of Coronary Artery Disease: A Substudy of the PROMISE Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41670958. doi:10.1001/jamacardio.2025.5520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。